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PATIENTS WITH SEVERE PERIPH-eral vascular disease frequentlyhaveunderlyingcoronaryarterydisease. Hence, patients under-
going major vascular surgery are at
increased risk for cardiac complications
during or shortly after surgery. Appro-
priatepatientmanagement then includes
assessment of the perioperative cardiac
risk, as well as strategies to reduce this
risk. Several investigations demon-
strated the utility of dobutamine stress
echocardiography (DSE) for preopera-
tive cardiac risk assessment.1-5 Patients
with stress-induced new wall-motion
abnormalities (NWMAs), a hallmark of
myocardial ischemia, areatan8%to38%
riskofcardiacdeathormyocardial infarc-
tion (MI) within 30 days after sur-
gery.2,4,6,7 In contrast, patients without
NWMAs have much lower complica-
tionrates: in therangeof0%to5%.There
are, however, significant disadvantages
associated with the routine use of DSE
(or other noninvasive imaging tech-
niques) in all vascular surgery candi-
dates.These include thesubstantial costs
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Context Patients who undergo major vascular surgery are at increased risk of peri-
operative cardiac complications. High-risk patients can be identified by clinical factors
and noninvasive cardiac testing, such as dobutamine stress echocardiography (DSE);
however, such noninvasive imaging techniques carry significant disadvantages. A re-
cent study found that perioperative b-blocker therapy reduces complication rates in
high-risk individuals.
Objective To examine the relationship of clinical characteristics, DSE results, b-blocker
therapy, and cardiac events in patients undergoing major vascular surgery.
Design and Setting Cohort study conducted in 1996-1999 in the following 8 cen-
ters: Erasmus Medical Centre and Sint Clara Ziekenhuis, Rotterdam, Twee Steden Ziek-
enhuis, Tilburg, Academisch Ziekenhuis Utrecht, Utrecht, and Medisch Centrum Alkmaar,
Alkmaar, the Netherlands; Ziekenhuis Middelheim, Antwerp, Belgium; and San Gerardo
Hospital, Monza, Istituto di Ricovero e Cura a Carattere Scientifico, San Giovanni Rotondo,
Italy.
Patients A total of 1351 consecutive patients scheduled for major vascular surgery;
DSE was performed in 1097 patients (81%), and 360 (27%) received b-blocker therapy.
Main Outcome Measure Cardiac death or nonfatal myocardial infarction within 30
days after surgery, compared by clinical characteristics, DSE results, and b-blocker use.
Results Forty-five patients (3.3%) had perioperative cardiac death or nonfatal myo-
cardial infarction. In multivariable analysis, important clinical determinants of adverse out-
come were age 70 years or older; current or prior angina pectoris; and prior myocardial
infarction, heart failure, or cerebrovascular accident. Eighty-three percent of patients had
less than 3 clinical risk factors. Among this subgroup, patients receiving b-blockers had a
lower risk of cardiac complications (0.8% [2/263]) than those not receiving b-blockers
(2.3% [20/855]), and DSE had minimal additional prognostic value. In patients with 3 or
more risk factors (17%), DSE provided additional prognostic information, for patients with-
out stress-induced ischemia had much lower risk of events than those with stress-
induced ischemia (among those receiving b-blockers, 2.0% [1/50] vs 10.6% [5/47]). More-
over, patients with limited stress-induced ischemia (1-4 segments) experienced fewer cardiac
events (2.8% [1/36]) than those with more extensive ischemia ($5 segments, 36% [4/11]).
Conclusion The additional predictive value of DSE is limited in clinically low-risk pa-
tients receiving b-blockers. In clinical practice, DSE may be avoided in a large number of
patients who can proceed safely for surgery without delay. In clinically intermediate- and
high-risk patients receiving b-blockers, DSE may help identify those in whom surgery can
still be performed and those in whom cardiac revascularization should be considered.
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of the test, and, more importantly, the
risk of delaying surgery in patients with
large aortic aneurysms or critical limb
ischemia. The recent Dutch Echo-
cardiographic Cardiac Risk Evaluation
Applying Stress Echocardiography
(DECREASE) study demonstrated that
perioperativeb-adrenergicblockadewith
bisoprolol reduces the risk of 30-day
complications in patients with NWMAs
toarisk levelasobservedinpatientswith-
out NWMAs.8,9 This finding raises the
question of whether DSE is indicated in
all patients scheduled for vascular
surgery. Does simple perioperative
administration of b-blockers reduce or
eliminate the need for noninvasive pre-
operative cardiac testing?10 On the other
hand, in some patients the cardiopro-
tective effect of b-blockers may be insuf-
ficient to effectively reduce periopera-
tive cardiac events. These patients may
benefit from additional coronary revas-
cularization. To address these issues
westudiedtherelationshipbetweenclini-
cal characteristics, DSE results, b-block-
ers, and adverse cardiac outcome in
a large series of consecutive patients
scheduled to undergo major vascular
surgery.
METHODS
Patients
The study population consisted of 1351
consecutive patients scheduled for
elective major vascular surgery who
were screened for eligibility for the
DECREASE study at 8 of the following
participating centers: Erasmus Medical
Centre and Sint Clara Ziekenhuis, Rot-
terdam, Twee Steden Ziekenhuis, Til-
burg, Academisch Ziekenhuis Utrecht,
Utrecht, and Medisch Centrum Alk-
maar, Alkmaar, the Netherlands; Ziek-
enhuis Middelheim, Antwerp, Bel-
gium; and San Gerardo Hospital, Monza,
Istituto di Ricovero e Cura a Carattere
Scientifico, San Giovanni Rotondo,
Italy.8 Per protocol, 846 patients with at
least 1 of the following risk factors un-
derwent DSE: age 70 years or older, an-
gina, prior MI, congestive heart failure,
treatment for ventricular arrhythmias,
treatment for diabetes mellitus, or lim-
ited exercise capacity. Two hundred
forty-five additional patients under-
went DSE at the discretion of the treat-
ing physician, based on other risk fac-
tors (eg, hyperlipidemia and smoking).
Thus, in total 1091 patients (81%) un-
derwent DSE. Perioperative b-blockers
were administered to 360 patients
(27%): 301 (22%) of the 1351 patients
were treated long-term with b-block-
ers, and 59 (5%) were randomized to re-
ceive b-blockers within the framework
of the DECREASE study. Eight pa-
tients who had extensive resting and/or
stress-induced ischemia were ex-
cluded from the DECREASE study. Four
of these underwent coronary artery by-
pass graft surgery, and 2 of them died
during this operation. The 2 surviving
patients subsequently underwent un-
eventful vascular surgery with periop-
erative b-blocker administration for car-
diac protection. The other 4 patients
underwent vascular surgery without
prior myocardial revascularization
and received b-blockers for cardiac
protection. None of the other non-
DECREASE patients received b-block-
ers for cardiac protection.
Dobutamine Stress
Echocardiography
Dobutamine stress echocardiography
was performed according to a stan-
dard protocol.11 The left ventricle was
divided into 16 segments and wall mo-
tion was scored on a 5-point ordinal
scale (1, normal wall motion; 2, mild
hypokinesis; 3, severe hypokinesis; 4,
akinesis; and 5, dyskinesis). The re-
sults of DSE were considered positive
if new wall-motion abnormalities
(NWMAs) occurred (ie, if wall mo-
tion in any segment worsened by $1
more grades during the test, with the
exception of akinesis becoming
dyskinesis). The extent and location of
ischemia were evaluated and a wall-
motion index was calculated, both at
rest and during peak stress.
End Point Definition
The study end point was a composite
of cardiac death or nonfatal MI (MI) oc-
curring during the period from screen-
ing until 30 days after surgery. An ad-
verse events committee adjudicated all
end points. Deaths were considered to
be cardiac related unless there was ex-
plicit evidence for a noncardiac cause.
Myocardial infarction was defined by
either a serum creatine kinase level of
more than 110 U/L with a myoglobin
isoenzyme fraction of more than 10%,
or by new Q waves faster than 30 mil-
liseconds in duration on the 12-lead
electrocardiogram.
Data Analysis
Univariable and multivariable logistic
regression analyses were applied to
evaluate the relations between a lim-
ited number of baseline clinical char-
acteristics, DSE results, b-blocker
therapy, and the composite end points
as outlined above. All variables that
reached a P value ,.50 in univariable
analysis entered the multivariable stage.
Multivariable models were con-
structed by backward deletion of the
least significant characteristics, apply-
ing the Akaike optimal information cri-
terion.12,13 Special attention was paid to
the extent to which DSE results and
b-blocker therapy contributed to the
prognostic information obtained from
clinical characteristics alone. Odds ra-
tios (ORs) and corresponding 95% con-
fidence intervals (CIs) are reported.
Despite the fact that the population
consisted of patients undergoing high-
risk surgery, the number of outcome
events appeared to be limited. There-
fore, there was a serious concern that
model overfitting would occur. To over-
come this, we limited the number of
candidate clinical variables to be in-
cluded in the model, whereby, particu-
larly, the results of prior risk model-
ing analyses in surgical patients were
considered.14-17 Furthermore, we ap-
plied a clinical risk model that was de-
veloped elsewhere to our data set, and
collapsed the clinical risk assessment
into 1 index variable. Subsequently, the
prognostic value of this risk index and
the additional and additive prognostic
value of DSE results and b-blocker
therapy were analyzed by logistic re-
gression analyses. We chose the risk in-
dex that was recently developed by Lee
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and colleagues17 in a data set of 4315
patients undergoing major noncar-
diac surgery, including 898 patients un-
dergoing vascular surgery. To com-
pose the Lee risk index, 1 point is
assigned to each of the following char-
acteristics: high-risk type of surgery,
known ischemic heart disease, a his-
tory of congestive heart failure, a his-
tory of cerebrovascular disease, diabe-
tes mellitus, and renal failure.
The performance of the risk models
was determined by the cardiac index,
which indicates how well a model rank-
orders patients with respect to their out-
comes; the cardiac index ranges from
0.5 (not predictive at all) to 1.0 (opti-
mal performance).18 In addition, the
Hosmer-Lemeshow statistic for good-
ness of fit is presented. The predictive
accuracy of the models was further
evaluated by bootstrapping tech-
niques.19 One hundred bootstrap
samples were drawn from the original
data set (with replacement) and the full
modeling process, including the step-
wise selection, was redone in every
bootstrap sample. The models devel-
oped in the bootstrap samples were sub-
sequently tested in the original data set.
This process provides a factor to cor-
rect for a possible overoptimism of the
cardiac index.20
Based on the results obtained by the
described modeling strategies, a risk
score was developed to estimate an in-
dividual patient’s risk of perioperative
cardiac death or MI. Furthermore, a
simple decision-tree is constructed to
help the physician decide in which pa-
tients to refer for noninvasive periop-
erative cardiac testing.
RESULTS
The primary patient characteristics are
described in TABLE 1. Obviously, pa-
tients receiving b-blockers during sur-
gery had a risk profile that was worse
than that of patients not taking such
medication because they had higher rate
of hypertension, ventricular arrhyth-
mias, and history of coronary disease.
Furthermore, patients receiving
b-blockers more frequently used other
cardiac medications than those who
were not receiving b-blockers. There
were 45 perioperative cardiac compli-
cations (3.3%): 31 patients had car-
diac death and another 14 nonfatal MI.
Univariable Models
In univariable analysis, a history of heart
failure was the most significant deter-
minant of adverse cardiac outcome
among the clinical variables examined
(TABLE 2). The subgroup of patients with
a history of heart failure (5% of the popu-
lation) had a more than 5-fold increase
in the risk of perioperative cardiac death
or MI compared with those without such
a history. Other important univariable
determinants of perioperative cardiac
complications were a history of MI, prior
cerebrovascular accident (CVA), cur-
rent or prior angina pectoris, and age 70
years and older. Patients taking cardiac
medications had higher event rates than
patients not taking such medication; sta-
tistical significance was observed for ni-
trates and angiotensin-converting en-
zyme (ACE) inhibitors. There was no
relationship between the type of sur-
gery and the composite end point.
Patients who did not undergo DSE
(ie, patients without clinical cardiac risk
factors) and those without NWMAs
during DSE had a significantly lower
cardiac death or MI rate than patients
with NWMAs during DSE (0.4% and
1.6% vs 13.5%, respectively (P,.001;
TABLE 3). Thus, NWMAs were strongly
predictive of adverse perioperative car-
diac outcome. Moreover, the extent of
stress-induced ischemia also provided
important prognostic information, as
the event rates ranged from 10.8% in
those with NWMAs in 1 to 4 segments
Table 1. Characteristics of the Population
Characteristics
Patients Who
Used b-Blockers*
Patients Who Did
Not Use b-Blockers P Value†
Patients, No. 360 (100) 991 (100)
Demographics
Age $70 years 156 (43) 425 (43) .9
Men 280 (78) 774 (78) .94
History
Hypertension 209 (59) 374 (39) ,.001
Diabetes mellitus 56 (16) 129 (13) .28
Ventricular arrhythmias 20 (6) 26 (3) .01
Current stable angina or prior angina 158 (44) 176 (18) ,.001
Prior myocardial infarction 210 (59) 281 (29) ,.001
Congestive heart failure 27 (8) 44 (5) .04
Percutaneous transluminal
coronary angioplasty
33 (9) 26 (3) ,.001
Coronary artery bypass graft surgery 66 (19) 100 (10) ,.001
Prior cerebrovascular accident 39 (11) 78 (8) .1
Pulmonary disease 49 (14) 122 (13) .58
Renal failure 19 (5) 36 (4) .21
Aortic valve stenosis 14 (4) 25 (3) .2
Long-term cardiac medication
Aspirin 134 (38) 274 (29) ,.01
Nitrates 94 (27) 113 (12) ,.001
Calcium antagonists 135 (38) 200 (21) ,.001
Angiotensin-converting
enzyme inhibitors
127 (36) 267 (28) ,.01
Lipid-lowering agents 120 (34) 166 (18) ,.001
Scheduled type of surgery
Infrainguinal reconstruction 125 (35) 338 (34)
Tube prosthesis 69 (19) 179 (18) .83
Aortic-femoral bypass graft 166 (46) 474 (48)
*b-blocker therapy included long-term users (n = 301) and patients randomized to bisoprolol as part of the Dutch Echo-
cardiographic Cardiac Risk Evaluation Applying Stress Echocardiography (DECREASE) study (n = 59). All data are
presented as number (percentage) unless otherwise indicated.
†Fisher exact 2-sided test.
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Table 2. Univariable Relation Between Clinical Baseline Characteristics and Perioperative Cardiac Death or Myocardial Infarction (N = 1351)*
Variables No. of Patients
Cardiac Death or
Myocardial Infarction, No. (%)
Odds Ratio
(95% Confidence Interval)
x2
Test P Value
Demographics
Age, y
$70 581 27 (4.7) 2.0 (1.1-3.7)
5.3 .02
,70 770 18 (2.3) 1.00
Sex
Men 1054 36 (3.4) 1.1 (0.5-2.4)
0.1 .74
Women 297 9 (3.0) 1.0
History
Congestive heart failure
Yes 71 10 (14.1) 5.7 (2.7-12.1)
20.8 ,.001
No 1255 35 (2.8) 1.0
Prior myocardial infarction
Yes 491 30 (6.1) 3.6 (1.9-6.8)
15.9 ,.001
No 846 15 (1.8) 1.0
Prior cerebrovascular accident
Yes 117 12 (10.3) 4.1 (2.0-8.1)
15.9 ,.001
No 1209 33 (2.7) 1.0
Current stable angina or prior angina
Yes 334 23 (6.9) 3.3 (1.8-6.0) 15.2 ,.001
No 998 22 (2.2) 4.1 (2.0-8.1) 15.9 ,.001
Diabetes mellitus
Yes 185 11 (6.0) 2.1 (1.0-4.2)
4.2 .04
No 1149 34 (3.0) 1.0
Renal failure
Yes 55 4 (7.3) 2.4 (0.8-6.9)
2.5 .11
No 1280 41 (3.2) 1.0
Aorta stenosis
Yes 39 3 (7.7) 2.5 (0.8-8.6)
2.3 .13
No 1292 41 (3.2) 1.0
Pulmonary disease
Yes 171 9 (5.3) 1.7 (0.8-3.6)
2.0 .15
No 1153 36 (3.1) 1.0
Ventricular arrhythmias
Yes 46 3 (6.5) 2.1 (0.6-6.9)
1.4 .24
No 1279 42 (3.3) 1.0
Coronary artery bypass graft surgery
Yes 166 8 (4.8) 1.5 (0.7-3.4)
1.2 .28
No 1159 37 (3.2) 1.0
Hypertension
Yes 583 23 (3.9) 1.3 (0.7-2.4)
0.9 .34
No 737 22 (3.0) 1.0
Percutaneous transluminal coronary angioplasty
Yes 59 1 (1.7) 0.5 (0.1-3.5)
0.5 .47
No 1261 44 (3.5) 1.0
Long-term Cardiac Medication
Nitrates
Yes 207 18 (8.7) 3.9 (2.1-7.2)
18.3 ,.001
No 1083 26 (2.4) 1.0
Angiotensin-converting enzyme inhibitors
Yes 394 20 (5.1) 1.9 (1.0-3.5)
4.4 .04
No 911 25 (2.7) 1.0
Calcium antagonists
Yes 335 15 (4.5) 1.5 (0.8-2.8)
1.6 .21
No 962 29 (3.0) 1.0
Aspirin
Yes 408 17 (4.2) 1.4 (0.7-2.5)
1.0 .32
No 879 27 (3.1) 1.0
Lipid-lowering agents
Yes 286 11 (3.8) 1.1 (0.6-2.3)
0.1 .72
No 997 34 (3.4) 1.0
Scheduled Type of Surgery
Infrainguinal reconstruction 463 15 (3.2) 0.9 (0.5-1.9) 0.0 .86
Tube prosthesis 248 8 (3.2) 0.9 (0.4-2.3) 0.0 .88
Aortic-femoral bypass graft 640 22 (3.4) 1.0
*Numbers may not add to 1351 due to missing data.
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to 23.9% in patients with NWMAs in
5 or more segments. The echocardio-
gram at rest also provided prognostic
information. Patients with 5 or more ab-
normal segments had a 4- to 6-fold in-
creased risk of cardiac complications
compared with those with a normal or
slightly aberrant (1-4 abnormal seg-
ments) wall motion at rest.
Despite their overall risk profile be-
ing worse (Table 1), patients receiving
b-blockers during surgery had a signifi-
cantly reduced risk of cardiac death or
MI compared with those not taking such
medication. Among the 254 patients
who did not undergo DSE, no periop-
erative cardiac complications were ob-
served in the 8.7% of patients receiving
b-blockers, whereas there was 1 event
(0.4%) in the remaining patients. In the
875 patients without stress-induced
NWMAs, 22% were receiving b-block-
ers. One cardiac complication (0.5%) oc-
curred in this group, and there were 13
(1.9%) in those not receiving b-block-
ers. Finally, in the 222 patients with
NWMAs, 67% of those receiving
b-blockers with 4.7% having a periop-
erative cardiac event vs 31.5% among
those not receiving b-blockers. There
was no evidence of a differential effect
of b-blocker therapy in these patient cat-
egories (homogeneity test for ORs,
P=.69), so that the crude OR is best es-
timated by the method of Mantel-
Haenszel test (0.1; 95% CI, 0.1-0.3).
Multivariable Models
Many of the univariably significant clini-
cal determinants of cardiac outcome re-
mained important in the multivariable
analysis (TABLE 4). After correcting for
other determinants, prior CVA showed
the strongest relationship with periop-
erative cardiac complications. A his-
tory of heart failure and prior MI were
the next strongest clinical predictors. An-
gina and age 70 years or more were also
important. After correcting for differ-
ences in clinical characteristics, pa-
tients receiving b-blockers were still at
significantly lower risk for the compos-
ite end point than those who were not
(adjusted OR, 0.3; 95% CI, 0.1-0.7).
When clinical data were combined
with DSE results, advanced age, angina
pectoris, prior MI, and prior heart fail-
ure lost most of their predictive power
with respect to the composite end point.
In fact, DSE results (especially the pres-
ence or absence of NWMAs) were the
most important determinants of periop-
erative cardiac outcome. In connection
with both clinical data and DSE results,
b-blocker therapy was again associated
with a significantly reduced risk of the
composite end point. The protective ef-
fect of b-blocker therapy was observed
in long-term users (OR, 0.1; 95% CI, 0.0-
0.3) as well as in patients who received
bisoprolol as part of the DECREASE
study (OR, 0.1; 95% CI, 0.0-0.4).
Application of the Lee Risk Index
In all, 611 patients (45%) had a Lee risk
index of 1, 509 (38%) had an index of
2, and 231 (17%) had an index of 3 or
more points (note that all patients un-
derwent high-risk surgery, and thus had
a risk index $1 points). The inci-
dence of the composite end point in
these patients was 1.3%, 3.1%, and 9.1%
(P,.001). Regression analysis re-
vealed a crude OR of 2.3 for the com-
posite end point associated with a
1-point increase in the risk index (95%
CI, 1.8-3.1). Multivariable analyses
again demonstrated the additional and
additive prognostic value of DSE re-
sults and b-blocker therapy (TABLE 5).
Predictive Accuracy
The cardiac index for the composite end
point model based on clinical character-
istics only was 0.78, reflecting good abil-
ity to discriminate between patients who
Table 3. Univariable Relation Between Dobutamine Stress Echocardiography Results and Perioperative Cardiac Death or Myocardial
Infarction*
Variables No. of Patients
Cardiac Death or
Myocardial Infarction, No. (%)
Odds Ratio
(95% Confidence Interval) x2 P Value
DSE summary
New wall-motion abnormalities 222 30 (13.5) 39.5 (5.3-292) 13.0 ,.001
No new wall-motion abnormalities 875 14 (1.6) 4.1 (0.5-8.1)
1.9 .17
No DSE 254 1 (0.4) 1.0
Segments with new wall-motion abnormalities, No.†
$5 46 11 (23.9) 19.3 (8.2-45.6) 45.7 ,.001
1-4 176 19 (10.8) 7.4 (3.7-15.2)
30.6 ,.001
0 875 14 (1.6) 1.0
Abnormal segments at rest, No.†
$5 305 29 (9.5) 5.8 (2.8-12.2) 22.3 ,.001
1-4 226 5 (2.2) 1.3 (0.4-3.7)
0.2 .68
0 566 10 (1.8) 1.0
ST-segment changes during test†
Yes 233 20 (8.6) 3.7 (1.9-6.9)
16.2 ,.001
No 839 21 (2.5) 1.0
Angina during test†
Yes 100 10 (10.0) 3.3 (1.6-7.0)
10.0 .002
No 986 32 (3.2) 1.0
*Numbers may not add to 1097 due to missing data.
†Results are based on analyses in the 1097 patients undergoing dobutamine stress echocardiography (DSE).
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did and did not have a life-threatening
cardiac complication. The associated
goodness of fit of the x27 statistic was 2.1
(P=.95). After correction for overopti-
mism the cardiac index was 0.72, still re-
flecting satisfactory performance. The
multivariable model that combined clini-
cal data with DSE results had consider-
ably better discriminating power with a
cardiac index of 0.87 (goodness of fit
x26=7.6, P=.27; optimism-corrected car-
diac index, 0.82). The cardiac index con-
nected with the Lee risk-index-alone
model was 0.71 (goodness of fit x26, 7.0;
P=.32) and improved to 0.87 by adding
DSE results and information regarding
b-blocker therapy.
Risk Classification Model
Based on the results described above, a
simple scheme was developed to esti-
mate a patient’s risk of perioperative car-
diac complications (FIGURE 1). A clini-
cal risk score can be determined on the
basis of the patient’s age and clinical
history. If this risk score is in the range
of 0 to 2 points (83% of the patients
belonged to this category) and the
b-blockers are administered periopera-
tively, the estimated cardiac complica-
tion rate is relatively low (,2%), irre-
spective of the DSE result. The estimated
risk of cardiac complications is also low
in patients with a risk score of 3 or more
points without NWMAs, provided
b-blockers will be applied. Patients with
a risk score of 3 or more and NWMAs
were at a considerable cardiac risk
(.6%), despite b-blocker therapy.
COMMENT
Consistent with other studies,14-17 our
analysis of 1351 patients undergoing
high-risk noncardiac vascular surgery
demonstrated that advanced age, cur-
rent or prior angina, and a history of
cardiac or cerebral events are the most
important clinical determinants of peri-
operative cardiac death or MI. Apart
from clinical data, DSE results were
highly predictive of adverse cardiac out-
come, which also confirms other inves-
tigations.1 Patients receiving b-block-
ers had significantly lower risk than
those not receiving them. It should be
emphasized that patients receiving
b-blockers had a considerably worse
overall risk profile than those not receiv-
ing them, which makes this result even
more convincing. The additional and
additive prognostic value of DSE results
and b-blocker therapy was confirmed
in the analysis that applied the previ-
ously developed Lee risk index. On the
basis of a risk score composed of a
weighted sum of the prognostic clini-
cal characteristics, a large group (83%)
of low-risk patients with a score of less
than 3 could be defined. In this group,
the estimated risk of cardiac complica-
tions is less than 1%, regardless of DSE
results, as long as patients are receiv-
ing b-blockers. In the remaining
patients, those without stress-induced
ischemia also had a low estimated car-
diac risk in the presence of periopera-
tive b-blocker therapy.
Table 4. Multivariable Models to Predict Perioperative Cardiac Death or Myocardial
Infarction*
Variables
Odds Ratio
(95% Confidence Interval) x2 P Value
Clinical Characteristics Only
Prior cerebrovascular accident
Yes 3.4 (1.6-7.3)
10.4 .001
No 1.0
Perioperative b-blocker therapy†
Yes 0.3 (0.1-0.7)
6.9 .009
No 1.0
Congestive heart failure
Yes 3.0 (1.3-6.9)
6.8 .009
No 1.0
Prior myocardial infarction
Yes 2.5 (1.2-5.3)
6.2 .01
No 1.0
Current stable angina or prior angina
Yes 2.1 (1.1-4.3)
4.7 .03
No 1.0
Age, y
$70 1.9 (1.0-3.6)
4.0 .05
,70 1.0
Combination of Clinical Characteristics
and Results of Dobutamine Stress Echocardiography
Segments with new wall-motion abnormalities, No.
$5 16.7 (6.0-47.0) 39.3 ,.001
1-4 13.9 (6.1-31.7)
28.5 ,.001
0 1.0
Perioperative b-blocker therapy†
Yes 0.1 (0.0-0.3)
22.7 ,.001
No 1.0
Abnormal segments at rest, No.
$5 3.0 (1.5-6.3)
8.8 .003
0-4 1.0
Prior cerebrovascular accident
Yes 3.2 (1.4-731)
7.6 .001
No 1.0
Age, y
$70 1.9 (1.0-4.0)
3.3 .07
,70 1.0
Congestive heart failure
Yes 2.3 (0.9-5.5)
3.1 .08
No 1.0
*Multivariable models were constructed by backward deletion of the least significant characteristics while applying the
Akaike information criterion (see “Methods” section).
†b-Blocker therapy includes long-term users and patients randomized to bisoprolol as part of the Dutch Echocardio-
graphic Cardiac Risk Evaluation Applying Stress Echocardiography (DECREASE) study.
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Univariable analyses showed that pa-
tients with diabetes mellitus, pulmo-
nary disease, prior ventricular arrhyth-
mias, or aortic valvular stenosis are at
increased risk of surgical complica-
tions. However, in contrast to earlier
studies,16,21 these factors were not in-
dependent predictors in our multivari-
able analyses. This finding can be re-
flect a changing patient population or
improved perioperative management al-
though it may also be a matter of (lack
of) power. Additionally, it should be
emphasized that cardiac death or MI
during complex surgery is most likely
to occur in patients with stress-
inducible cardiac ischemia. Indeed, the
occurrence of NWMAs during DSE was
a major determinant of adverse out-
come. Because a stress-induced ische-
Figure 1. Estimate of the Perioperative Risk of Cardiac Death or Myocardial Infarction
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Results are based on clinical characteristics and results of DSE in patients who received b-blockers and those who did not receive b-blockers. Results reflect predictions
based on logistic regression analyses.
Table 5. Model for the Prediction of Cardiac Death or Myocardial Infarction
by the Lee Risk Index, Dobutamine Stress Echocardiography Results,
and Perioperative b-Blocker Therapy
Variables
Odds Ratio
(95% Confidence Interval) x2 P Value
Segments with new wall-motion
abnormalities, No.
$5 11.6 (4.4-30.5) 24.8 ,.001
1-4 6.7 (3.1-14.5) 23.1 ,.001
0 1.0
Perioperative b-blocker therapy*
Yes 0.2 (0.1-0.6) 10.4 .001
No 1.0
Abnormal segments at rest, No.
$5 2.7 (1.3-5.5) 7.1 .008
0-4 1.0
Lee risk index†
1-Point increase 1.6 (1.1-2.2) 6.5 .01
*b-Blocker therapy includes long-term users and patients randomized to bisoprolol as part of the Dutch Echocardio-
graphic Cardiac Risk Evaluation Applying Stress Echocardiography (DECREASE) study.
†To compose the Lee risk index, 1 point is assigned to each of the following characteristics: high risk type of surgery,
known ischemic heart disease, a history of congestive heart failure, a history of cerebrovascular disease, diabetes
mellitus, and renal failure.
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mia was not more common in patients
with diabetes mellitus, pulmonary dis-
ease, prior ventricular arrhythmias, or
aortic stenosis (78 NWMAs of 352 cases
[22%]) than in patients without such
characteristic (144 NWMAs of 745
cases [19%]; P=.28), these character-
istics are likely not strong determi-
nants of a predisposition to ischemia.
In contrast, patients with prior MI, prior
heart failure, or prior CVA were more
likely to have stress-induced ischemia
than other patients (150 NWMAs of
545 cases [28%] vs 72 NWMAs of 552
cases [13%]; P,.001). Still, factors such
as diabetes mellitus, may be predic-
tive of long-term complications. Dia-
betes mellitus (and renal failure) were
therefore still incorporated in the clini-
cal risk index (Figure 1).
Clinical Implications
FIGURE 2 may help to understand how
results can be translated into clinical
practice. The perioperative cardiac event
rate was low ($1%) in patients with a
clinical risk score of less than 3 points
and who were receiving b-blockers. It
seems therefore appropriate to omit DSE
(and other noninvasive cardiac test-
ing) in this large (.80%) group of pa-
tients and to proceed expeditiously with
surgery under protection by b-blocker
therapy. Dobutamine stress echocardi-
ography is useful to further risk-
stratify patients with a clinical risk score
of 3 or more points. If protected by peri-
operative b-blockade, patients without
stress-induced ischemia still had a low
complication rate (2%) and are also can-
didates for prompt surgery. Patients with
a risk score of 3 or more points and
NWMAs (approximately 6% of the
population) had a considerable compli-
cation rate despite the b-blocker therapy.
Our data suggest that the proposed treat-
ment policy in these patients may de-
pend on the extent of stress-induced is-
chemia. Although the numbers of
patients and events are relatively small
in the specific subgroups, patients with
NWMAs in 1 to 4 segments were prop-
erly protected by b-blockers. In pa-
tients with more extensive ischemia,
however, b-blockers failed to reduce the
rate of perioperative cardiac complica-
tions. Cardiac catheterization and sub-
sequent myocardial revascularization
should be considered in these patients.
The prescription of b-blockers may
delay surgery; so far, no study has indi-
cated what the optimal run-in period
of this drug is in this setting. There-
fore, it can be questioned whether such
therapy is really necessary in patients
at very low risk. In the group of patients
with a risk score of 0 points, 1.2% peri-
operative complications were observed
in thosewithoutb-blocker therapy(Fig-
ure2).This complication rate seemssuf-
ficiently low to refrain from adminis-
tering medication indeed and opt for
surgery without delay. Another issue is
that b-blocker therapy may be contra-
indicated, especially in patients with
reactive airway diseases, such as severe
asthma or chronic obstructive pulmo-
nary disease with a reactive compo-
nent. It should be noticed that these
patients are rare: there were no such
cases in our data set. Still, if b-blocker
therapy is contraindicated, the use of
calcium antagonists with a negative
chronotropic effect may be consid-
ered. The recent Incomplete Infarc-
tion Trial of European Research Col-
laborators Evaluating Prognosis post-
Thrombolysis (INTERCEPT) study of
post-MI patients reported fewer car-
diac events in patients randomized to
such a drug compared with placebo.22
Study Limitations
Because of its retrospective nature, our
analysis has limitations, which should
be considered when interpreting the re-
sults. The risk-stratification and modi-
fication scheme using a clinical risk
score, DSE, and b-blocker therapy was
developed after events had occurred.
Furthermore, only some patients (those
participating in the DECREASE study)
were randomized to receive either peri-
operative b-blockers or standard care.
Patient characteristics may have played
Figure 2. Perioperative Cardiac Risk of Death or Myocardial Infarction as Observed
in Subpopulations
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an important role in the decision to ad-
minister b-blockers to patients who did
not participate in the DECREASE study
and could potentially bias the results.
Importantly, we found no difference in
the cardioprotective effect of b-block-
ers between patients who were random-
ized within the framework of the
DECREASE study and those whose re-
ceipt of b-blockers was chronic. This
suggests that the utility of periopera-
tive b-adrenergic blockade extends
beyond the small subset of high-risk
patients who participated in the
DECREASE study. Finally, the ob-
served event rates were relatively low
compared with previous investiga-
tions. It should be appreciated that our
results were obtained in selected, high-
volume hospitals (3 of the participat-
ing hospitals were university hospi-
tals) and that cardiac event rates might
differ in other centers.
Conclusions
Dobutamine stress echocardiography ef-
fectively identifies patients at risk for
perioperative cardiac events. Besides, our
data showed that the additional predic-
tive value of DSE is limited in clinically
low-risk patients receiving b-blockers.
This observation may have important
clinical implications: in a majority of pa-
tients, additional testing by DSE can be
avoided and patients can proceed safely
for surgery without delay. In a smaller
group of clinically intermediate- and
high-risk patients, DSE may help to iden-
tify patients in whom surgery can still
be performed while receiving b-block-
ers and those in whom cardiac revascu-
larization should be considered.
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